Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB, Slater RM, Harbott J, Seyfarth J, van Wering ER, Hählen K, Schmiegelow K, Janka-Schaub GE, Veerman AJ. Ramakers-van Woerden NL, et al. Among authors: van drunen e, van wering er. Blood. 2000 Aug 1;96(3):1094-9. Blood. 2000. PMID: 10910927 Free article.
In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia.
Ramakers-van Woerden NL, Pieters R, Slater RM, Loonen AH, Beverloo HB, van Drunen E, Heyman M, Moreno TC, Rots MG, van Wering ER, Kamps WA, Janka-Schaub GE, Veerman AJ. Ramakers-van Woerden NL, et al. Among authors: van drunen e, van wering er. Br J Haematol. 2001 Mar;112(3):680-90. doi: 10.1046/j.1365-2141.2001.02586.x. Br J Haematol. 2001. PMID: 11260073 Free article.
Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.
Stams WA, Beverloo HB, den Boer ML, de Menezes RX, Stigter RL, van Drunen E, Ramakers-van-Woerden NL, Loonen AH, van Wering ER, Janka-Schaub GE, Pieters R. Stams WA, et al. Among authors: van drunen e, van wering er. Leukemia. 2006 Mar;20(3):410-6. doi: 10.1038/sj.leu.2404083. Leukemia. 2006. PMID: 16424874
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Löwenberg B, Delwel R. Lugthart S, et al. Among authors: van drunen e, van norden y, van hoven a. Blood. 2008 Apr 15;111(8):4329-37. doi: 10.1182/blood-2007-10-119230. Epub 2008 Feb 13. Blood. 2008. PMID: 18272813 Free article.
Novel murine B-cell lymphoma/leukemia model to study BCL2-driven oncogenesis.
Meijerink JP, Van Lieshout EM, Beverloo HB, Van Drunen E, Mensink EJ, Macville M, Pieters R. Meijerink JP, et al. Among authors: van drunen e, van lieshout em. Int J Cancer. 2005 May 10;114(6):917-25. doi: 10.1002/ijc.20822. Int J Cancer. 2005. PMID: 15645425 Free article.
Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.
Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hählen K, Poppe B, Van Roy N, Marynen P, De Paepe A, Slater R, Speleman F. Van Limbergen H, et al. Among authors: van drunen e, van roy n. Genes Chromosomes Cancer. 2001 Mar;30(3):274-82. Genes Chromosomes Cancer. 2001. PMID: 11170285
52 results